SMARCA2 levels were correlated with good prognosis in published datasets for breast and ovarian cancer, lung adenocarcinoma, and liposarcoma, and in the LIHC and KIRC TCGA cohorts. This evidence concerns the gene SMARCA2 and ovarian cancer.